GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss

-

 

GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss










By Elana Gotkine, HealthDay Reporter

TUESDAY, Jan. 21, 2025 -- For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for specific disorders and conditions, including neurocognitive and cardiometabolic disorders and with an increased risk for others, including gastrointestinal and arthritic disorders, according to a study published online Jan. 20 in Nature Medicine.

Yan Xie and colleagues from the VA St. Louis Health Care System examined the effectiveness and risks of GLP-1 RAs. The authors used the U.S. Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated a GLP-1 RA. They compared them to patients initiating sulfonylureas, dipeptidyl peptidase 4 (DPP4) inhibitors, or sodium-glucose cotransporter-2 (SGLT2) inhibitors (215,970, 159,465, 117,989, and 258,614 individuals, respectively). They were also compared to a control group composed of equal proportions of individuals initiating sulfonylureas, DPP4 inhibitors, and SGLT2 inhibitors (536,068 people), as well as a control group that continued use of non-GLP-1 RA antihyperglycemics (usual care; 1,203,097 individuals). The associations of GLP-1 RA use with each comparator were examined for 175 health outcomes.

The researchers found that GLP-1 RA use, compared with usual care, was associated with a reduced risk for substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses, and several respiratory conditions. Conversely, GLP-1 RA use was associated with an increased risk for gastrointestinal disorders, hypertension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis compared with usual care.

"Our discovery approach confirms previous studies and clinical trials and also uncovers previously unreported benefits and risks of GLP-1 RAs," the authors write. "The results may be useful for informing clinical care."

Two authors disclosed ties to Pfizer.

Comments

Post a Comment

Popular posts from this blog

Learn How the NEW Nutrition Facts Label Can Help You Improve Your Health

-
Image
  Learn How the NEW Nutrition Facts Label Can Help You Improve Your Health The US Food and Drug Administration (FDA) issued new regulations changing the  Nutrition Facts  label external  icon  on packaged foods. This is the first major change to the label since it was introduced in 1994. The changes are based on updated science, the most  recent dietary  recommendations, external  icon , and public input. Using the new label can help you choose foods for a healthy diet. The label will be required on all packaged foods made in the United States and imported from other countries. The new label is already appearing on packages. Most items will have the new label by January 1, 2021. What is changing? Calories & Fat Larger, darker letters make calories the easiest item to see on the new label. When it comes to health outcomes, the type of fat you eat matters more than the overall amount of fat. For this reason, the label will no longer show the per...
Read more

WHAT PERSONALITY TRAITS IMPACT YOUR ACTIVITY LEVEL?

-
Image
  YOUR PERSONALITY IMPACTS YOUR ACTIVITY LEVEL A study conducted at the Gerontology Research Centre and the Faculty of Sport and Health Sciences at the University of Jyväskylä observed associations of personality traits with physical activity and sedentary behavior . Individuals characterized by high conscientiousness and extraversion are likelier to accumulate more extended periods of physical activity and sedentary behavior. In contrast, individuals with higher neuroticism scores tend to interrupt their sedentary behavior more often. Your personality might influence how you move throughout the day, not how you think. A fascinating study from Finland's University of Jyväskylä has uncovered some surprising connections between who we are and how we move. Think of the friend who can't sit still and is constantly fidgeting or who goes for long, scheduled runs. These behaviors might be tied to personality traits. The researchers tracked the same people aged 33, 42, 50, and 61, exam...
Read more

FDA Approves Generic GLP-1 Medicine For Diabetes Treatment

-
Image
  FDA Approves Generic GLP-1 Medicine For Diabetes Treatment Big news for anyone wrestling with Type 2 diabetes: the FDA just gave the green light to a cheaper version of a popular diabetes drug. Think of it as the store-brand equivalent of Victoza – the same active ingredient (liraglutide), but likely easier on your wallet. If you've been following the Ozempic craze, you might recognize the family resemblance. Liraglutide is a cousin to semaglutide, the superstar ingredient in Ozempic. While everyone's been talking about these drugs for weight loss, their original purpose was helping people manage diabetes. The timing couldn't be better. With Ozempic and similar drugs flying off the shelves faster than hotcakes, this new generic version could help keep supplies steady. It's a big deal considering more than 38 million Americans are living with Type 2 diabetes – that's more people than the entire population of Canada. Here's how it works: Type 2 diabetes occurs w...
Read more